Evidence map›Paper›PMID 42186741›Full record

ArticleSmall methods2026

Engineered CRISPR/Cas12a2 Nanoprobe Imaging in Living Cells for Precise Tumor Diagnosis.

Junru Li, Chen Ji, Wenzhi Yang, Yongming Han, Peipei Zhao, Xiaohan Cai, Siqi Tian, Wenjing Zhu, Jingjing Zhang, Jinxinyi Xu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Junru LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chen JiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wenzhi YangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yongming HanState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Peipei ZhaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaohan CaiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Siqi TianState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wenjing ZhuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jingjing ZhangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jinxinyi XuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Weiqiang YangEmergency Department, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fengqin LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Peifeng LiuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0003-0731-2376

Funding

2024 National Clinical Key Specialty Construction Project 10000015Z155080000004Foundation of Shanghai Municipal Health Commission 2022JC002Foundation of Shanghai Municipal Health Commission 20234Y0201Jiading District Medical Key Discipline Construction Project XK202401Medical-Engineering Joint Funds from the Shanghai Jiao Tong University YG2023ZD07Medical-Engineering Joint Funds from the Shanghai Jiao Tong University YG2024QNB09National Key Scientific Infrastructure for Translational Medicine (Shanghai) TMSK-2024-203National Natural Science Foundation of China 22474077National Natural Science Foundation of China 32371468National Natural Science Foundation of China U25C2029Shanghai Municipal Natural Science Foundation 22ZR1459600Shanghai Municipal Natural Science Foundation 23ZR1461400
6 · The paper itself

Abstract

Messenger RNA (mRNA) imaging in tumor cells plays a crucial role in monitoring the occurrence and development of tumors. However, achieving highly specific and sensitive mRNA imaging remains a significant challenge due to the complex intracellular environment and high background signal. Here, we engineered a CRISPR/Cas12a2 system with an RNA blocking strand that binds to CRISPR RNA (crRNA). After glutathione (GSH) stimulation, the RNA blocking strand is cleaved, allowing the release of crRNA and restoring the capability of CRISPR/Cas12a2 ribonucleoprotein (RNP). Furthermore, we developed a nanoprobe (termed eRNP-FHR) by converging engineered Cas12a2 RNP (eRNP) with framework-hotspot reporters (FHR). FHR features four vertices that modify the sgc8 aptamer to specifically target the protein tyrosine kinase 7 receptor on the surface of tumor cell membranes, link to the eRNP by hybridizing with crRNA, and incorporate fluorescence quenching groups. The eRNP-FHR precisely targets tumor cells through aptamer-mediated endocytosis, specifically recognizes mRNA upon GSH stimulation, and simultaneously cleaves FHR to release a significant fluorescent signal. Excitingly, eRNP-FHR successfully achieved imaging of baculoviral IAP repeat-containing 5 mRNA in pancreatic tumor cells, accurately distinguishing pancreatic tumor cells from normal cells. In a murine pancreatic tumor model, eRNP-FHR exhibited excellent mRNA imaging, highlighting significant potential for precise tumor diagnosis.

Indexed as

CRISPR-Cas SystemsNeoplasmsAnimalsCell Line, TumorCRISPR-Associated ProteinsGlutathioneHumansMiceMolecular ImagingRNA, MessengerCRISPR-Associated ProteinsGlutathioneRNA, MessengerBIRC5 mRNAcell imagingCRISPR/Cas12a2DNA frameworknanoprobe

Identifiers

PMID42186741
PMCPMC13244425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.